These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

992 related articles for article (PubMed ID: 12814710)

  • 1. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
    Collins R; Armitage J; Parish S; Sleigh P; Peto R;
    Lancet; 2003 Jun; 361(9374):2005-16. PubMed ID: 12814710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
    Heart Protection Study Collaborative Group
    Lancet; 2002 Jul; 360(9326):7-22. PubMed ID: 12114036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
    Collins R; Armitage J; Parish S; Sleight P; Peto R;
    Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].
    Heart Protection Study Collaborative Group
    BMC Med; 2005 Mar; 3():6. PubMed ID: 15771782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.
    Heart Protection Study Collaborative Group
    J Vasc Surg; 2007 Apr; 45(4):645-654; discussion 653-4. PubMed ID: 17398372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
    Baigent C; Landray MJ; Reith C; Emberson J; Wheeler DC; Tomson C; Wanner C; Krane V; Cass A; Craig J; Neal B; Jiang L; Hooi LS; Levin A; Agodoa L; Gaziano M; Kasiske B; Walker R; Massy ZA; Feldt-Rasmussen B; Krairittichai U; Ophascharoensuk V; Fellström B; Holdaas H; Tesar V; Wiecek A; Grobbee D; de Zeeuw D; Grönhagen-Riska C; Dasgupta T; Lewis D; Herrington W; Mafham M; Majoni W; Wallendszus K; Grimm R; Pedersen T; Tobert J; Armitage J; Baxter A; Bray C; Chen Y; Chen Z; Hill M; Knott C; Parish S; Simpson D; Sleight P; Young A; Collins R;
    Lancet; 2011 Jun; 377(9784):2181-92. PubMed ID: 21663949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.
    Eur Heart J; 1999 May; 20(10):725-41. PubMed ID: 10329064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpretation of the evidence for the efficacy and safety of statin therapy.
    Collins R; Reith C; Emberson J; Armitage J; Baigent C; Blackwell L; Blumenthal R; Danesh J; Smith GD; DeMets D; Evans S; Law M; MacMahon S; Martin S; Neal B; Poulter N; Preiss D; Ridker P; Roberts I; Rodgers A; Sandercock P; Schulz K; Sever P; Simes J; Smeeth L; Wald N; Yusuf S; Peto R
    Lancet; 2016 Nov; 388(10059):2532-2561. PubMed ID: 27616593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.
    Heart Protection Study Collaborative Group
    Lancet; 2002 Jul; 360(9326):23-33. PubMed ID: 12114037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
    ; Armitage J; Bowman L; Wallendszus K; Bulbulia R; Rahimi K; Haynes R; Parish S; Peto R; Collins R
    Lancet; 2010 Nov; 376(9753):1658-69. PubMed ID: 21067805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
    Baigent C; Landray M; Leaper C; Altmann P; Armitage J; Baxter A; Cairns HS; Collins R; Foley RN; Frighi V; Kourellias K; Ratcliffe PJ; Rogerson M; Scoble JE; Tomson CR; Warwick G; Wheeler DC
    Am J Kidney Dis; 2005 Mar; 45(3):473-84. PubMed ID: 15754269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
    Heart Protection Study Collaborative Group
    Lancet; 2011 Dec; 378(9808):2013-2020. PubMed ID: 22115874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
    Mihaylova B; Briggs A; Armitage J; Parish S; Gray A; Collins R;
    Lancet; 2005 May 21-27; 365(9473):1779-85. PubMed ID: 15910950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
    Sharp Collaborative Group
    Am Heart J; 2010 Nov; 160(5):785-794.e10. PubMed ID: 21095263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
    Cholesterol Treatment Trialists' Collaboration
    Lancet; 2019 Feb; 393(10170):407-415. PubMed ID: 30712900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
    ; Mihaylova B; Emberson J; Blackwell L; Keech A; Simes J; Barnes EH; Voysey M; Gray A; Collins R; Baigent C
    Lancet; 2012 Aug; 380(9841):581-90. PubMed ID: 22607822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of the month. The MRC/BHF Heart Protection Study].
    Kulbertus H; Scheen AJ
    Rev Med Liege; 2002 Sep; 57(9):613-6. PubMed ID: 12440352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study.
    ; Jonathan Emberson ; Derrick Bennett ; Emma Link ; Sarah Parish ; John Danesh ; Jane Armitage ; Rory Collins
    Lancet; 2011 Feb; 377(9764):469-76. PubMed ID: 21277016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.